

**Stephania Librerros, Ph.D.**

Assistant Professor  
Department of Pathology  
Vascular Biology and Therapeutics Program  
Yale Cancer Center  
Yale School of Medicine  
New Haven, CT  
Lab website: <https://librerros-lab.com>

**Education:** Dr. Stephania Librerros completed her B.S. in Microbiology, Molecular Cell Biology, and Biotechnology, M.S. in Molecular Cell Biology, and Ph.D. in Integrative Biology/Immunology at Florida Atlantic University. She then pursued postdoctoral training

at Harvard Medical School in the laboratory of Dr. Charles N. Serhan, where she contributed to defining the biosynthesis and functions of specialized pro-resolving lipid mediators in leukocyte signaling, phagocytosis, and host defense. Dr. Librerros served as an Instructor in Anesthesia at Harvard Medical School before joining the Yale faculty in 2023 as a tenure-track Assistant Professor in the Department of Pathology, with appointments in the Vascular Biology and Therapeutics Program, the Yale Cancer Center, and the Yale Cooperative Center of Excellence in Hematology. Her transition to independence was supported by an NIH/NHLBI K99/R00 Pathway to Independence Award.

**Professional Activities**

*Editorial Boards:* Associate Editor, *Journal of Leukocyte Biology*, 2025–present; Early Career Researcher Editorial Board, FASEB (Federation of American Societies for Experimental Biology), 2026–present.

*Honors:* Image of the Year, Society for Leukocyte Biology (1st Prize, 2025); Society for Leukocyte Biology Early Career Award (2nd Place, 2023); Eicosanoid Research Foundation Santosh Nigam Outstanding Young Scientist Award (2022); Vanderbilt University Basic Sciences Rising Star in Biomedical Research (2022); Intersectional Science Fellow (2021); Outstanding Poster Award, Gordon Research Conference "Phagocytes" (2019); Brigham and Women's Hospital Research Excellence Award (2016); Florida Atlantic University Integrative Biology Program Alumni Award (2016); SLB Student Presidential Award (2015); Society for Leukocyte Biology–FASEB MARC Minority Travel Award (2014, 2013); American Association for Cancer Research Minority Scholar Award (2012–2014).

*Society for Leukocyte Biology — Service:*

- Co-founder and Chair, Members in Transition and Training Committee (MTTC), 2014–2020
- Co-founder, SLB Poster Flash Talks
- Junior Editor, iSLB Newsletter, 2014–2016
- Co-Chair, SLB Satellite Symposium "Resolution of Inflammation," 2019
- Active member since undergraduate trainee, 2010–present

*Other Service:* Member, Yale Department of Pathology DICE Committee, 2025–present; Member, TMMPP PhD Admissions Committee, Yale Department of Pathology, 2024–present; Mentor, Continuing Umbrella of Research Experience (CURE) Program, Dana-Farber/Harvard Cancer Center, 2016–2022; Mentor, Mentoring Circles Program, Brigham and Women's Hospital/Harvard Medical School, 2022–2023; Treasurer (2018–2019) and Chair of the Advocacy Committee (2016–2018), Harvard Medical School Postdoctoral Association.

## Research Interests

Acute inflammation is a self-limited program where resolution is actively orchestrated by coordinated leukocyte responses, efferocytic clearance of apoptotic cells, and the reprogramming of immune cells from pro-inflammatory to pro-resolving phenotypes. When these programs fail, unresolved inflammation drives the pathogenesis of sepsis, cancer, and cardiovascular disease. **My laboratory investigates the biochemical, cellular, and immunometabolic mechanisms that govern resolution, and defines how their dysregulation sustains chronic inflammatory disease.** Our work centers on three questions. **First**, how do myeloid heterogeneity and metabolic networks integrate to terminate inflammation and reestablish tissue homeostasis? **Second**, what molecular signals and metabolic cues encode the temporal switches that govern leukocyte trafficking, phagocyte effector function, and tissue repair? **Third**, which molecular networks are dysregulated in patients whose inflammation fails to resolve? We address these questions by integrating mechanistic studies in murine models of acute and chronic inflammation with translational analyses of patient-derived blood, tissue, and primary immune cells from cohorts with sepsis, cancer, and other inflammatory pathologies. Our long-term objective is to develop resolution-based therapeutics that restore endogenous pro-resolving programs and reinstate tissue homeostasis in disease.

## Statement of Interest

I delivered my first scientific presentation at an SLB meeting as an undergraduate, and I remember walking into that meeting without a sense of belonging. But the Society welcomed me with open arms and from that moment on, SLB has been my scientific home, the community that gave me my first mentors, my first platforms, and the connections that turned a curious undergraduate into a faculty member. I cannot imagine my career without this Society, and that is precisely why I want to serve it.

I have had the opportunity to serve SLB in several roles. I served as the first Junior Editor of iSLB from 2014 to 2018, because trainees deserved a deliberate voice inside our newsletter. I co-founded the Members in Transition and Training Committee (MTTC) and chaired it for six years, from 2014 to 2020, so that no trainee would navigate the long, uncertain stretch between the bench and independence alone. Through MTTC, we established the SLB Poster Flash Talks, a platform built to put trainee science on stage, which has since become a pillar of our annual meeting. I have also co-chaired the SLB Satellite Symposium on Resolution of Inflammation.

Chairing MTTC gave me a working view of how SLB Council operates. I sat in conversations and contributed to decisions that directly shaped trainee programming, and I saw firsthand how deeply the Council and the Society invested in training the next generation of leukocyte biologists. I know what this seat can do for trainees, and I am ready to do the work.

If elected, I will deliver three concrete commitments alongside MTTC. **First**, close the postdoc-to-PI gap with structured peer-mentoring cohorts, K-to-R chalk talks, and mock study sections, so trainees enter independence prepared, not alone. **Second**, continue building the non-academic career pipeline through standing programming with industry, biotech, and government scientists, so the full breadth of leukocyte biology careers is visible and our members in those sectors stay engaged with SLB. **Third**, keep our community international and inclusive by expanding hybrid programming, growing trainee travel awards for under-resourced institutions and countries, and advocating for international members facing visa and mobility barriers. I will also commit to the part of this role that is most important: listening. Quarterly listening sessions with MTTC, regular check-ins with trainee committee leads, and a clear feedback channel into Council, so trainee experience continuously shapes what SLB becomes.

This Society has been shaped by many people who cared, and I have been honored to be among them. I would be privileged to serve as Associate Councilor and to be a voice on Council for every undergraduate, graduate student, and postdoc who joins SLB hoping to find their place, the way I once did.